Reporting positive treatment outcomes with bendamustine + rituximab in indolent lymphomas
How can doctors discuss CLL treatment options with patients?
Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies
Clinical trials, pathologies and developments in personalized medicine
Francesco d'Amore et al.
The goals and work of the European Research Initiative on CLL (ERIC)